CDK4 and pulmonary arterial hypertension: The abundance of the CDK4 disulfide is decreased in pulmonary arteries and pulmonary arterial smooth muscle cells from patients with idiopathic PAH; while therapeutic benefits are provided by the pharmacological inhibition of redox cycling using a thioredoxin reductase inhibitor, which increases disulfide accumulation in experimental models of PH.